1/2상모집 중단 (진행 중)
Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants
연구 개요
This study is the first study of Sanofi's Pentavalent Meningococcal ABCYW vaccine clinical development program to be conducted in the pediatric population below 10 years of age. The aim of the study is to assess 2 formulations of the MenPenta vaccine compared to licensed meningococcal vaccines when administered alone in children (Stage 1) or concomitantly with routine pediatric vaccines in toddlers (Stage 2) and infants (Stage 3). Study details include: The study duration per participant will be up to 12 months for children in Stage 1 and toddlers in Stage 2 and 16 to-19 months for infants in Stage 3.
- 스폰서
- 리드: 사노피
- 적응증
- Meningococcal Immunization, Healthy Volunteers
- 중재
- Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Paracetamol, DTap-HepB-IPV-Hib vaccine, DTap-HepB-IPV-Hib vaccine, DTap-HepB-IPV-Hib vaccine, Rotavirus vaccine, Pneumococcal 13-valent conjugate vaccine
- 목표 등록
- 750명
- 시작일
- 2024-11-05
- 완료(예정)
- 2027-05-17
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.